{"id":530683,"date":"2021-02-17T16:58:01","date_gmt":"2021-02-17T16:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=530683"},"modified":"2021-02-17T16:58:01","modified_gmt":"2021-02-17T16:58:01","slug":"presbyopia-competitive-analysis-report-2020-emerging-therapies-and-key-pharma-players-involved","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/presbyopia-competitive-analysis-report-2020-emerging-therapies-and-key-pharma-players-involved_530683.html","title":{"rendered":"Presbyopia Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1613540755.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Presbyopia Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved\" src=\"https:\/\/www.abnewswire.com\/uploads\/1613540755.jpeg\" alt=\"Presbyopia Competitive Analysis Report 2020: Emerging Therapies and Key Pharma Players Involved\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">&#8220;Presbyopia Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Presbyopia market. A detailed picture of the Presbyopia pipeline landscape is provided, which includes the disease overview and Presbyopia treatment guidelines.\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/presbyopia-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Presbyopia Pipeline Insights 2020<\/strong><\/a>.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span data-mce-mark=\"1\">&#8220;<\/span><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/presbyopia-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong><span data-mce-mark=\"1\">Presbyopia Pipeline Insight, 2020<\/span><\/strong><\/a><span data-mce-mark=\"1\">&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<\/span><span data-mce-mark=\"1\">Presbyopia&nbsp;<\/span><span data-mce-mark=\"1\">market. A detailed picture of the&nbsp;<\/span><span data-mce-mark=\"1\">Presbyopia&nbsp;<\/span><span data-mce-mark=\"1\">pipeline landscape is provided, which includes the disease overview and&nbsp;<\/span><span data-mce-mark=\"1\">Presbyopia&nbsp;<\/span><span data-mce-mark=\"1\">treatment guidelines.&nbsp;<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span data-mce-mark=\"1\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/b5559d207c479ee891ffcdb5c29845c0.jpg\" alt=\"\" \/><\/span><\/p>\n<div class=\"O0\" style=\"text-align: justify;\">Presbyopia is the normal loss of near focusing ability that occurs with age. Most people begin to notice the effects of presbyopia sometime after age 40. It is a result of a gradual decrease in accommodative amplitude, from about 15 diopters (D) to 1 D. This typically comes on between the ages of 40 and 60 as the lenses of the eyes naturally lose elasticity due to the ageing process.<\/div>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Request for sample pages of the report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/presbyopia-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><span data-sheets-value=\"{\" data-sheets-userformat=\"{\">https:\/\/www.delveinsight.com\/sample-request\/presbyopia-pipeline-insight<\/span><\/a><\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li class=\"ql-align-justify\">The&nbsp;Presbyopia&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for<\/em><strong><em>&nbsp;<\/em><\/strong>Presbyopia&nbsp;across the complete product development cycle, including all clinical and non-clinical stages.<\/li>\n<li class=\"ql-align-justify\"><span>It comprises of&nbsp;<\/span><em>detailed profiles of&nbsp;<\/em><span>Presbyopia&nbsp;<\/span><em>therapeutic products<\/em><span>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/span><\/li>\n<li class=\"ql-align-justify\"><span>Detailed&nbsp;<\/span><span>Presbyopia&nbsp;<\/span><em>research and development progress and trial details<\/em><span>, results wherever available, are also included in the pipeline study.<\/span><\/li>\n<li class=\"ql-align-justify\"><em>Coverage of dormant and discontinued pipeline project<\/em><span>s along with the reasons if available across&nbsp;<\/span><span>Presbyopia<\/span><span>.<\/span><\/li>\n<\/ul>\n<div style=\"text-align: justify;\"><strong>&#8220;Several types of surgery are available, and new techniques and technologies are making them safer and more effective. Refractive surgical procedures include conductive keratoplasty, LASIK, LASEK, and photorefractive keratectomy.&#8221;<\/strong><\/div>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><strong>Key pharma players involved:<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">1. Orasis Pharmaceuticals Ltd<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">2. Allergan<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">3. Novartis Pharmaceuticals<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/presbyopia-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Click here and get access to free sample copy.<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\"><span>2. Presbyopia&nbsp;<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">3. Presbyopia&nbsp;Current Treatment Patterns<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">4. Presbyopia&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">6. Presbyopia Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\"><span>7. Presbyopia Mid Stage Products (Phase-II)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8. Early Stage Products (Phase-I)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9. Pre-clinical Products and Discovery Stage Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10. Inactive Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11. Dormant Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12. Presbyopia Discontinued Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>13. Presbyopia&nbsp;Product Profiles<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">14. Presbyopia&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\"><span>15. Presbyopia&nbsp;Key Products<\/span><\/p>\n<p style=\"text-align: justify;\"><span>16. Dormant and Discontinued Products<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">17. Presbyopia&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\"><span>18. Presbyopia&nbsp;Future Perspectives<\/span><\/p>\n<p style=\"text-align: justify;\"><span>19. Presbyopia&nbsp;Analyst Review&nbsp;&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\"><span>20. Appendix<\/span><\/p>\n<p style=\"text-align: justify;\"><span>21. Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><strong>Download our full report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/presbyopia-pipeline-insight?utm_source=ABnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/presbyopia-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><span>About DelveInsight<\/span><br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=presbyopia-competitive-analysis-report-2020-emerging-therapies-and-key-pharma-players-involved\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=presbyopia-competitive-analysis-report-2020-emerging-therapies-and-key-pharma-players-involved\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP &#8220;Presbyopia Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Presbyopia market. A detailed picture of the Presbyopia pipeline landscape is provided, which includes the disease &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/presbyopia-competitive-analysis-report-2020-emerging-therapies-and-key-pharma-players-involved_530683.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-530683","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=530683"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/530683\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=530683"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=530683"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=530683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}